Search - tctmd.com

Displaying 261 - 280 of 527

Sort: Relevancy | Date

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

L.A. McKeown

January 21, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Todd Neale

November 20, 2019

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Daily News

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Marcus A. Banks

July 31, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

Advertisement

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Grief and CVD: Simple Regimen May Lower Risk

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Recurrent Events Common Among Young Patients With CAD

TCTMD’s Top 10 Most Popular Stories for September 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content